Glypromate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Glypromate
DrugBank Accession Number
DB05633
Background

Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the potential treatment of neurodegenerative diseases by IV infusion. In December 2008, the company discontinued further development of the drug after it failed to show an observable effect.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 301.299
Monoisotopic: 301.127385344
Chemical Formula
C12H19N3O6
Synonyms
  • Gly-pro-glu
  • Glycyl-prolyl-glutamic acid
  • GPE

Pharmacology

Indication

Investigated for use/treatment in neurologic disorders.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
ZYK4RVV5LS
CAS number
32302-76-4
InChI Key
JJGBXTYGTKWGAT-YUMQZZPRSA-N
InChI
InChI=1S/C12H19N3O6/c13-6-9(16)15-5-1-2-8(15)11(19)14-7(12(20)21)3-4-10(17)18/h7-8H,1-6,13H2,(H,14,19)(H,17,18)(H,20,21)/t7-,8-/m0/s1
IUPAC Name
(2S)-2-{[(2S)-1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}pentanedioic acid
SMILES
[H]N([H])CC(=O)N1CCC[C@H]1C(=O)N([H])[C@@H](CCC(O)=O)C(O)=O

References

General References
Not Available
ChemSpider
2338502
ChEMBL
CHEMBL371315
ZINC
ZINC000003776571

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility14.7 mg/mLALOGPS
logP-3.2ALOGPS
logP-4.9Chemaxon
logS-1.3ALOGPS
pKa (Strongest Acidic)3.2Chemaxon
pKa (Strongest Basic)7.83Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area150.03 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity69.08 m3·mol-1Chemaxon
Polarizability28.23 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0zir-1933000000-08b1efc68d25f16e2d85
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-1459000000-c8ce5a572e3333b677db
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-3910000000-a6f08975edbaf0ed5fc3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f9w-1910000000-dbabf0b69f8288865a07
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-9500000000-541754a025867b7ff283
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00pl-8910000000-44408bb3760d555be428
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-169.8925219
predicted
DarkChem Lite v0.1.0
[M+H]+169.1303219
predicted
DarkChem Lite v0.1.0
[M+Na]+168.4730219
predicted
DarkChem Lite v0.1.0

Drug created at November 18, 2007 18:26 / Updated at June 12, 2020 16:52